Clinical trials

84

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Participants needed: 15
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 13, 2026Locations: 1
Eligibility criteria

Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to pr... [+2]

Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resect... [+2]

Status: Recruiting

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jul 1, 2026Locations: 1
Eligibility criteria

Histologic or radiographic diagnosis of hepatocellular carcinoma [+21]

Any type of previous systemic anti-cancer treatment [+43]

Status: Recruiting

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; 2) high levels of depressive symptoms and stigma; and 3) malnutrition, which negatively impacts the activation and proliferation of immune cells. Yet programs that offer WLH with comprehensive services focused on HPV screening and psychological and nutritional support are almost non-existent, and the gap is critical. Nutrition plays an integral role in relationship to HPV/HIV co-infection, as demonstrated by an increased risk of HR-HPV associated with poor nutrition; nutritional deficiencies are likewise linked to cervical intra-epithelial neoplasia. The immunological effect of malnutrition may also be exacerbated among WLH due to elevated energy demands of chronic immune activation; worsened with HPV/HIV co-infection. Further, depressive symptoms (aka depression for brevity) partially mediate the effect of food insecurity on HIV viral suppression. In our completed ASHA-Nutrition R01 study of antiretroviral (ART) adherence, the investigators trained lay community health workers, named Accredited Social Health Activist (ASHA), to improve the health of 600 rural WLH by providing emotional support, skill-building, nutrition education, and/or protein-enriched food supplements. In that study, our intervention, co-delivered by our trained ASHA, and guided by nurses, led to increased CD4+ T cell recovery and improved anthropometric and psychosocial outcomes. The investigators found that ASHA support plus protein supplements and nutritional education were significantly associated with improved CD4 counts and increased lean mass at 18 months (P \< 0.001), as well as significant improvements in depression, ART adherence, social support and internalized stigma. In our sub study, CC screening of 598 of these WLH revealed that 13% were found to have abnormal cervical lesions and 4 (1%) had squamous CC. Preliminary evidence also revealed that nutritional supplements may be associated with a 40% reduction in the risk of abnormal cervical lesions (adjusted odds ratio \[aOR\] = 0.60), with an association between serum albumin and reduced risk of abnormal lesions (aOR= 0.39). With a focus on secondary prevention of CC, the investigators hope to mitigate the link between HR-HPV persistence and risk of CC as well as improve the health of women co-infected with HPV/HIV (W-Co-V). Our stellar team plans to build upon our prior ASHA-Nutrition intervention, using formative research to refine a nurse-led, ASHA co-delivered, nutrition-enhanced SAKHI HPV intervention, adapted for W-Co-V. This will be followed by a randomized controlled trial (RCT), assessing the efficacy of our refined comprehensive, multifaceted SAKHI HPV intervention, as compared with an enhanced Standard of Care (SOC+) (usual care + 3 sessions \[wellness, basic nutrition and HPV/HIV health promotion\]) among 348 high-risk co-infected women to prevent CC while remaining engaged in the HIV treatment cascade, and managing nutritional health. Recruited participants will be individually randomized in a 1:1 ratio into the two study arms. Our Primary outcome is HR-HPV persistence (2 positive tests for the same HR-HPV type, separated by 12-18 months). The two aims incorporating RCT interventions are as follows: Aim 2. To evaluate the efficacy of SAKHI HPV intervention among 348 W-Co-V on the primary outcome (HR-HPV persistence) as compared to the Enhanced Standard of Care (SOC+) program. H2: Compared to the SOC+ participants, SAKHI participants will have lower rates of HR-HPV persistence. Aim 3. Assess the impact of the SAKHI program secondarily on: 1) HIV indices (HIV viral load; CD4 count); 2) Nutritional index (serum albumin) at 6-, 12-, and 18-months.

Participants needed: 348
Trial details
Age: 25-50Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Jun 26, 2026Locations: 3
Eligibility criteria

WLH, 25 - 50 years of age; based on HIV-based guidelines; [+3]

Pregnant or lactating women due to hormonal and dietary guideline differences; [+1]

Status: Recruiting

The Effects of Core Shamanism in Fibromyalgia

This study aims to determine the feasibility of a shamanism intervention for patients with fibromyalgia, acquire efficacy data to determine if Shamanism reduces clinical pain and other common symptoms associated with fibromyalgia, and determine if the Shamanism intervention changes heart rate electrocardiogram (ECG), breathing rate, and brain wave electroencephalogram (EEG) outcomes in fibromyalgia patients and shamanic practitioners. The investigators hypothesize that 80% of individuals will complete at least 80% of study visits, clinical pain severity and/or interference will be significantly reduced following the Shamanic intervention, and lung, heart, and/or brain activity will be altered with the Shamanic intervention and also become more synchronized between Shamanic Practitioners (SPs) and patients during the course of treatment.

Participants needed: 25
Trial details
Age: 18-75Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Female [+8]

Presence of a concurrent autoimmune or inflammatory disease such as rheumatoid a... [+17]

Status: Recruiting

Treatment of Meniere's Disease With Migraine Medications

Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability). Vertigo represents one of the most common and distressing problems in MD patients, and it causes various somatic and psychological disorders that interfere with the patient's quality of life. Despite the large economic and emotional impact of symptoms in MD patients, there is no FDA-approved medication to treat this debilitating condition. As such, our objective in this study is to evaluate the therapeutic potential of novel medications in treating MD that have previously shown astonishing promise in our clinical practice.

Participants needed: 40
Trial details
Phase: Phase 4Age: 25-85Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 22, 2026Locations: 1
Eligibility criteria

Patients with active or frequent Meniere's Disease. [+3]

Pregnancy will result in automatic exclusion from the study. A urine pregnancy t... [+6]

Status: Recruiting

Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture

This study aims to see whether acupuncture can help fibromyalgia patients by giving them acupuncture treatment and seeing whether acupuncture helps enhance the effects of an opioid.

Participants needed: 45
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Are 18 - 80 years old [+3]

Are younger than 18 or older than 80 years old [+5]

Status: Recruiting

Acoustic and Electrical Stimulation for the Treatment of Tinnitus

Tinnitus, or ringing in the ears, affects 10% to 30% of the population. Of those, 20% have tinnitus bothersome enough to seek medical attention. In many people, tinnitus can significantly affect the quality of life. At this point in time, there is no effective treatment or cure available for tinnitus. It has been found that electrical stimulation of the inner ear can reduce and in some cases eliminate tinnitus. The purpose of this research is to investigate both acoustic and electrical stimulation of the inner ear as a possible treatment of tinnitus. In both acoustic and electrical testing conditions, the subjects will be instructed to be familiar with a 0-10 ranking scale of loudness. In acoustic testing, the stimulus will be presented through headphones in a noiseless environment, and the subject will be asked to report on the loudness of the presented sound and the level of the tinnitus at 20-second intervals. If the subject cannot perceive the presence of the tinnitus, a value of zero will be assigned. A typical sound will be presented for 3 to 6 minutes. Loudness will be reported for 1 to 4 minutes after stimulus offset to measure the presence and duration of residual inhibition. Electrical stimulation will be delivered to the inner ear in three ways, 1. using a cochlear implant (implant placed in the inner ear to replace hearing function), 2. Using an electrode placed in the ear canal, and 3. using a small needle inserted through the ear drum. Various electrical signals will be used to evaluate the reduction in the tinnitus perception by the subject. The subjects will rate the loudness of the tinnitus before, during, and after the electrical signal. Surveys will be used to evaluate the tinnitus loudness and the quality of life of the subjects. Hearing tests will be used before and after the procedures. The long term goal of this research is to develop a device to treat tinnitus in people who can hear and to develop programs for cochlear implants that help treat tinnitus in deaf people.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 11, 2026Locations: 1
Eligibility criteria

18 years or older [+4]

Aged less than 18 years [+7]

Status: Recruiting

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric surgery.

Participants needed: 120
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Male and female subjects aged 18-70 years [+5]

Type 1 diabetes [+32]

Status: Not yet recruiting

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.

Participants needed: 35
Trial details
Phase: Phase 2Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 5, 2026Locations: 1
Eligibility criteria

≥18 years at the time of signing informed consent form (ICF) and able to indepen... [+15]

Participants with visceral, bone, or brain metastases. [+19]

Status: Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

Participants needed: 25
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Jun 5, 2026Locations: 1
Eligibility criteria

Age: Subjects must be 18 years of age or older. [+10]

Brain Metastases: Subjects with uncontrolled or symptomatic brain metastases. Su... [+11]

Status: Not yet recruiting

Chatbot for Online Support Groups to Treat Tobacco Addiction

Investigators will conduct a pilot RCT to test the efficacy of an intelligent chatbot to aid small, private, quit-smoking peer support groups. Participants will be randomized to an intervention arm (chatbot-enhanced support group), or a control arm (support group only). In the intervention arm (N=60), each support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). The intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so. In the control arm (N=60), the support groups will be connected to an automated message-posting bot running on a secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot. But both the intelligent chatbot and the automated message-posting bot will post a pre-written daily discussion topic to encourage participants to discuss issues known to facilitate tobacco cessation or group bonding.

Participants needed: 120
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 22, 2026
Eligibility criteria

Cigarette smokers (can also use e-cigarettes) [+10]

No NRT health contraindications [+3]

Status: Recruiting

Mapping Ibogaine Neural Dynamics in Opioid Use Disorder

This study aims to understand how ibogaine treatment may change brain activity and symptoms in people with moderate-severe opioid use disorder (OUD), as defined by the DSM-5. Ibogaine is a plant-derived compound that some studies suggest can reduce opioid cravings and withdrawal. Participants in this study will already be independently scheduled to receive legal ibogaine treatment at a licensed clinic outside of the U.S. The University of California, Irvine (UCI) research team will not provide the treatment but will conduct brain imaging, administer psychometric questionnaires, and obtain urine samples throughout the course of this study. UCI does not sponsor or financially support the ibogaine treatment in any way; all treatment costs are the sole responsibility of the participant. The main goal is to see if ibogaine changes brain function as assessed with magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and electroencephalography (EEG). MRI/MRS will measure brain activity when participants view opioid-related images, brain connectivity at rest, and levels of brain chemicals involved in craving and substance use. EEG will measure brain wave activity. MRI/MRS/EEG will be administered across 3 study time points. In addition, participants will complete psychometric surveys related to opioid craving, withdrawal symptoms, mood, anxiety, pain, and quality of life, along with urine tests to monitor substance use and screen for pregnancy. The investigators hypothesize that after ibogaine treatment, participants will show reduced brain responses to opioid cues, changes in brain connectivity and chemistry, and improvements in self-reported cravings and other symptoms. This information may help researchers better understand how ibogaine works in the brain and whether it could play a role in future treatments for OUD.

Participants needed: 20
Trial details
Age: 21-70Biological sex: AllType: ObservationalSponsor: University of California, IrvineUpdated: May 18, 2026Locations: 1
Eligibility criteria

Adults aged 21-70 with confirmed moderate to severe OUD as assessed by equal or... [+7]

Presence of known past procedures, devices in the body, claustrophobia, or other... [+8]

Status: Recruiting

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Participants needed: 12
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 12, 2026Locations: 2
Eligibility criteria

Participants must be greater than 18 years of age. [+7]

Individuals currently receiving or received Reiki treatment in the past 30 days [+2]

Status: Recruiting

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

Participants needed: 22
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 11, 2026Locations: 1
Eligibility criteria

Patients must have histologically or cytologically confirmed adenocarcinoma of t... [+16]

Patients who have had major surgery within 4 weeks, or chemotherapy or radiother... [+9]

Status: Recruiting

Telemedicine to Support Living Kidney Donor Candidates

The goal of this feasibility clinical trial is to learn if telemedicine can be used to provide education and evaluation and counseling for people who are considering living kidney donation. The study will also learn how participants improve decision-making about living kidney donation. The main questions to answer are: * Is telemedicine a practical way to facilitate donor education and evaluation and counseling? * Does telemedicine shared decision making help improve donor candidate decision and engagement during the donor evaluation process? Researchers will compare standard care with a telemedicine care coordination approach. Participants will: \- Receive either standard care or telemedicine video visits to support shared decision making.

Participants needed: 70
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 5, 2026Locations: 1
Eligibility criteria

18 years of age or older [+2]

Status: Recruiting

Positive Affect Treatment for Adolescents With Early Life Adversity

Youth exposed to early life adversity (ELA) are known to be at greater risk for depression and suicidality and account for almost half of the youth suffering from psychiatric diseases today. Youth exposed to ELA consistently report symptoms of anhedonia as well as dysregulated positive affect. The present project will test the efficacy of PAT in a sample of ELA-exposed adolescents in order to determine whether PAT increases positive affect, and subsequently symptoms of depression. For the initial pilot phase of the investigation, the investigators will recruit up to 30 adolescents exposed to two or more childhood adversities (ACEs) who do not currently have major depressive disorder, and randomize them (1:1) to either participate in PAT or a waitlist control condition. For the second phase of the investigation, the investigators will recruit up to 300 adolescents exposed to two or more childhood adversities (ACEs) who do not currently have major depressive disorder, and randomize them (1:1) to either participate in PAT or supportive psychotherapy. For both phases, at study enrollment, then 4-, 8, and 12-months thereafter the investigators will measure positive affect and depressive symptoms (including anhedonia and reward sensitivity). The results of this study will be used to inform whether PAT has the potential to prevent major depressive episodes among adversity-exposed youth.

Participants needed: 300
Trial details
Age: 12-16Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 6, 2026Locations: 1
Eligibility criteria

aged 12-16 [+1]

currently taking an antidepressant or any medications known to influence immune... [+4]

Status: Recruiting

De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

This is a single-arm, observational registry study determining the effects of reduced radiation dose in select patients with human papillomavirus (HPV) positive oropharyngeal cancer.

Participants needed: 111
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University of California, IrvineUpdated: May 5, 2026Locations: 1Duration: 2 Years
Eligibility criteria

Pathologically (histologically or cytologically) proven (from primary lesion and... [+6]

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease f... [+3]

Status: Not yet recruiting

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.

Participants needed: 60
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: University of California, IrvineUpdated: May 6, 2026Locations: 1
Eligibility criteria

Age 18 years or greater at time of consent [+4]

Prior treatment for any prostate malignancy (e.g. radiation, focal therapy, or s... [+4]

Status: Recruiting

PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)

This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.

Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 4, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years old [+13]

Uncontrolled significant clinical illness [+15]

Status: Recruiting

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.

Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 4, 2026Locations: 1
Eligibility criteria

≥18 years of age [+8]

Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3 [+12]

Status: Recruiting

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

Participants needed: 23
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Apr 30, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years at the time of study consent. [+22]

Underwent a partial cystectomy or partial nephrectomy. [+28]

Status: Recruiting

mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer

This is a pilot, single arm, prospective study that aims to validate the accuracy of the VI-RADS score obtained via multi-parametric magnetic resonance imaging (mpMRI) compared to pathologic cancer stage obtained via diagnostic transurethral bladder tumor resection (TURBT) as well as compare the clinical and quality of life outcomes between these diagnostic modalities in patients with suspected muscle-invasive bladder cancer (MIBC).

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: May 4, 2026Locations: 1
Eligibility criteria

Age 18 years old or greater at the time of consent. [+4]

Prior TURBT within 120 days of study entry. [+5]

Status: Not yet recruiting

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).

Participants needed: 102
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of California, IrvineUpdated: Apr 29, 2026
Eligibility criteria

Histologic or pathologic diagnosis of stage III-IV epithelial ovarian, fallopian... [+11]

Prior history of any cancer (other than non-melanoma skin cancer) [+11]

Status: Recruiting

Latinx Children and Surgery

Over 60 million persons in the United States (US) identify themselves as Latinx and 25.6% are children under the age of 16. Surgical disparities for adults and children have been identified as a major problem in the US and can be experienced at multiple points along a patient's health care trajectory. Data from the investigator's center indicates that a substantial portion of Latinx children who undergo surgery experience high anxiety and postoperative pain as well as postoperative impairments in psychological and physical functioning as compared to White non-Latin children who undergo surgery. Recent growth in use of mobile devices provides us an opportunity to create low-cost mobile health (mHealth) behavioral interventions to reduce this disparity in surgical outcomes. In a previous National Institutes of Health (NIH) award, the principal investigator (PI) developed and tested an evidence based mHealth tailored intervention (WebTIPS) that aims to prepare and be a companion of a child and their family during a surgical event. WebTIPS aims to enhance the recovery of the child in several ways such as reducing anxiety and pain and is based on information provision, modeling, and teaching of coping skills. WebTIPS, however, was developed and validated with a population of primarily White non-Latinx English-speaking children and their parents. Unfortunately, it is well established that mHealth interventions are significantly less effective when used with specific ethnic minorities unless they underwent a process of cultural adaptation. Over the past 4-years, the investigators have established multiple academic and community collaborations, conducted extensive participatory research with Latinx stakeholders and used the heuristic framework and a modified ecological validity model to culturally adapt WebTIPS. The culturally adapted intervention is called L-WebTIPS. The overall aim of this application is to reduce surgical disparities in a population of Latinx children undergoing surgery. The first phase of this application (R61) includes web programming of L-WebTIPS, and a feasibly randomized control trial (RCT) to test this intervention. The second phase (R33) includes a multi-center RCT which aims to determine the effectiveness of L-WebTIPS compared to attention control intervention in decreasing postoperative pain, opioids consumption and lowering anxiety in Latinx children undergoing outpatient surgery. Secondary aims of the R33 include examining the impact of L-WebTIPS on home-based clinical recovery parameters such as pain, analgesic requirements, new onset behavioral changes and return to normal daily activity in Latinx children undergoing outpatient surgery. The investigators also plan to determine if the use of L-WebTIPS reduces anxiety and improve experience among the parents of Latinx children undergoing surgery. Finally, the investigators plan to determine if the use of L-WebTIPS reduces anxiety and enhance experience among the parents of Latinx children undergoing surgery. The investigators submit that using a cultural adaption process for an existing validated intervention will accelerate the process of reducing surgical disparities and bringing an effective intervention to clinical settings and routine use.

Participants needed: 120
Trial details
Age: 2-7Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Apr 14, 2026Locations: 1
Eligibility criteria

Children age 2-7 who are scheduled to undergo outpatient surgery. [+3]

Children with health status defined by ASA status IV-V will be excluded from thi... [+5]

Status: Recruiting

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.

Participants needed: 44
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: University of California, IrvineUpdated: Apr 13, 2026Locations: 2
Eligibility criteria

Male and female subjects aged 18-65 years [+6]

Hiatal hernia >2cm (defined as maximum axial height from end of the esophagus to... [+19]